V

Viking Therapeutics

VKTX

54.610
USD
-2.38
(-4.18%)
مفتوح الان
حجم التداول
58,036
الربح لكل سهم
0
العائد الربحي
0
P/E
-67
حجم السوق
6,894,847,526
أصول ذات صلة
C
CRBP
-0.500
(-0.84%)
59.160 USD
G
GALT
-0.27000
(-10.80%)
2.23000 USD
G
GNFT
0.10000
(2.41%)
4.25000 USD
I
ICPT
0
(0%)
0.000000 USD
M
MDGL
-6.22
(-2.18%)
278.97 USD
الأخبار المقالات

العنوان: Viking Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.